病例报告：1例2019冠状病毒病患者在免疫调节治疗后发生播散性单纯疱疹病毒1型感染和噬血细胞性淋巴组织细胞增生症
Case report: Disseminated herpes simplex virus 1 infection and hemophagocytic lymphohistiocytosis after immunomodulatory therapy in a patient with coronavirus disease 2019.
作者信息
Mazzotta Elvio, Fiorda Diaz Juan, Echeverria-Villalobos Marco, Eisinger Gregory, Sprauer Sarah, Singha Arindam, Lyaker Michael R
机构信息
Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine and Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
出版信息
Front Med (Lausanne). 2022 Nov 21;9:1053012. doi: 10.3389/fmed.2022.1053012. eCollection 2022.
Corticosteroids and immunomodulatory therapies are widely used to treat patients with severe coronavirus disease 2019 (COVID-19). Janus kinase (JAK) inhibitors such as tofacitinib have been recently studied as adjuvants in the treatment of COVID-19. Although immunomodulatory therapies may be linked to decreased mortality rates in the acute phase, subsequent severe infectious complications may result from them. We describe a case of a multiorgan system failure secondary to disseminated primary herpes simplex virus 1 (HSV-1) infection and hemophagocytic lymphohistiocytosis (HLH) following treatment with tofacitinib and high-dose dexamethasone therapy for severe COVID-19. Early diagnosis and treatment of these life-threatening conditions may have a significant impact on COVID-19 patients' outcomes.
皮质类固醇和免疫调节疗法被广泛用于治疗重症2019冠状病毒病（COVID-19）患者。托法替布等Janus激酶（JAK）抑制剂最近已作为COVID-19治疗的佐剂进行研究。尽管免疫调节疗法可能与急性期死亡率降低有关，但随后可能会导致严重的感染并发症。我们描述了一例在使用托法替布和高剂量地塞米松治疗重症COVID-19后，继发播散性原发性单纯疱疹病毒1型（HSV-1）感染和噬血细胞性淋巴组织细胞增生症（HLH）的多器官系统衰竭病例。对这些危及生命的病症进行早期诊断和治疗可能会对COVID-19患者的预后产生重大影响。
Zotero 插件